Anti-TSPAN8/anti-CD3 bispecific antibody and anti-TSPAN8 antibody

Patent metadata

Field	Value
Publication number	US-11897954-B2
Application number	US-202117639783-A
Country	US
Kind code	B2
Filing date	Nov 15, 2021
Priority date	Nov 16, 2020
Publication date	Feb 13, 2024
Grant date	Feb 13, 2024

Abstract

An objective of the present invention is to provide an anti-TSPAN8/anti-CD3 bispecific antibody and an anti-TSPAN8 antibody usable in treatment or prevention in human. A human monoclonal antibody producing mouse was immunized with a peritoneal disseminated cancer cell isolated from a patient, to obtain an antibody 16B11 and an antibody 16B12 that selectively bind to a peritoneal disseminated cancer cell. These antibodies were anti-TSPAN8 antibodies that bind to the region from amino acid positions 126 to 155 of TSPAN8 and exhibited strong binding activity to TSPAN8 expressed in the peritoneal disseminated cancer cell. Further, an anti-TSPAN8(16B11)-anti-CD3 bispecific antibody produced based on the sequence of 16B11 exhibited a cytotoxic activity against the TSPAN8-expressing cancer cell in vitro, exerted an anti-tumor action on TSPAN8-expressing cancer cell-bearing mice in vivo, and extended the lifetime of peritoneal dissemination model mice.

First claim

The invention claimed is:

1. A bispecific antibody that binds to TSPAN8 and CD3, comprising:
(a) a Fab region of an anti-TSPAN8 antibody consisting of: a heavy chain fragment comprising a heavy chain variable region of the anti-TSPAN8 antibody; and a light chain comprising a light chain variable region of the anti-TSPAN8 antibody;
(b) an anti-CD3-scFv region comprising a heavy chain variable region and a light chain variable region of an anti-CD3 antibody; and
(c) a Fc region consisting of a first Fc polypeptide linked to the heavy chain fragment of the Fab region (a) and a second Fc polypeptide linked to the anti-CD3-scFv region (b),
wherein
the heavy chain variable region of the anti-TSPAN8 antibody comprises a CDR1 consisting amino acids 31 to 35 of SEQ ID NO: 6, a CDR2 consisting of amino acids 50 to 66 of SEQ ID NO: 6, and a CDR3 consisting of amino acids 99 to 110 of SEQ ID NO: 6, and the light chain variable region of the anti-TSPAN8 antibody comprises a CDR1 consisting of amino acids 24 to 34 of SEQ ID NO: 8, a CDR2 consisting of amino acids 50 to 56 of SEQ ID NO: 8, and a CDR3 consisting of amino acids 89 to 96 of SEQ ID NO: 8; or
the heavy chain variable region of the anti-TSPAN8 antibody comprises a CDR1 consisting of amino acids 31 to 35 of SEQ ID NO: 10, a CDR2 consisting of amino acids 50 to 66 of SEQ ID NO: 10, and a CDR3 consisting of amino acids 99 to 110 of SEQ ID NO: 10, and the light chain variable region of the anti-TSPAN8 antibody comprises a CDR1 consisting of amino acids 24 to 34 of SEQ ID NO: 12, a CDR2 consisting of amino acids 50 to 56 of SEQ ID NO: 12, and a CDR3 consisting of amino acids 89 to 96 of SEQ ID NO: 12.

2. The bispecific antibody according to claim 1 , wherein the heavy chain variable region of the anti-TSPAN8 antibody comprises a CDR1 consisting amino acids 31 to 35 of SEQ ID NO: 6, a CDR2 consisting of amino acids 50 to 66 of SEQ ID NO: 6, and a CDR3 consisting of amino acids 99 to 110 of SEQ ID NO: 6, and the light chain variable region of the anti-TSPAN8 antibody comprises a CDR1 consisting of amino acids 24 to 34 of SEQ ID NO: 8, a CDR2 consisting of amino acids 50 to 56 of SEQ ID NO: 8, and a CDR3 consisting of amino acids 89 to 96 of SEQ ID NO: 8.

3. The bispecific antibody according to claim 1 , wherein the heavy chain variable region of the anti-TSPAN8 antibody comprises a CDR1 consisting of amino acids 31 to 35 of SEQ ID NO: 10, a CDR2 consisting of amino acids 50 to 66 of SEQ ID NO: 10, and a CDR3 consisting of amino acids 99 to 110 of SEQ ID NO: 10, and the light chain variable region of the anti-TSPAN8 antibody comprises a CDR1 consisting of amino acids 24 to 34 of SEQ ID NO: 12, a CDR2 consisting of amino acids 50 to 56 of SEQ ID NO: 12, and a CDR3 consisting of amino acids 89 to 96 of SEQ ID NO: 12.

4. The bispecific antibody according to claim 1 , wherein the heavy chain variable region of the anti-TSPAN8 antibody consists of amino acids 1 to 121 of SEQ ID NO: 6, and the light chain variable region of the anti-TSPAN8 antibody consists of amino acids 1 to 107 of SEQ ID NO: 8.

5. The bispecific antibody according to claim 1 , wherein the heavy chain variable region of the anti-TSPAN8 antibody consists of amino acids 1 to 121 of SEQ ID NO: 10, and the light chain variable region of the anti-TSPAN8 antibody consists of amino acids 1 to 107 of SEQ ID NO: 12.

6. The bispecific antibody according to claim 1 , wherein the Fab region of the anti-TSPAN8 antibody consists of a heavy chain fragment consisting of amino acids 1 to 219 of SEQ ID NO: 6 and a light chain consisting of an amino acid sequence of SEQ ID NO: 8.

7. The bispecific antibody according to claim 1 , wherein the Fab region of the anti-TSPAN8 antibody consists of a heavy chain fragment consisting of an amino acid sequence from amino acid positions 1 to 219 of SEQ ID NO: 10 and a light chain consisting of an amino acid sequence of SEQ ID NO: 12.

8. The bispecific antibody according to claim 1 , wherein the heavy chain variable region of the anti-CD3 antibody comprises a CDR1 consisting of amino acids 31 to 35 of SEQ ID NO: 14, a CDR2 consisting of amino acids 50 to 68 of SEQ ID NO: 14, and a CDR3 consisting of amino acids 101 to 114 of SEQ ID NO: 14, and the light chain variable region of the anti-CD3 antibody comprises a CDR1 consisting of amino acids 168 to 181 of SEQ ID NO: 14, a CDR2 consisting of amino acids 197 to 203 of SEQ ID NO: 14, and a CDR3 consisting of amino acids 236 to 244 of SEQ ID NO: 14.

9. The bispecific antibody according to claim 2 , wherein the heavy chain variable region of the anti-CD3 antibody comprises a CDR1 consisting of amino acids 31 to 35 of SEQ ID NO: 14, a CDR2 consisting of amino acids 50 to 68 of SEQ ID NO: 14, and a CDR3 consisting of amino acids 101 to 114 of SEQ ID NO: 14, and the light chain variable region of the anti-CD3 antibody comprises a CDR1 consisting of amino acids 168 to 181 of SEQ ID NO: 14, a CDR2 consisting of amino acids 197 to 203 of SEQ ID NO: 14, and a CDR3 consisting of amino acids 236 to 244 of SEQ ID NO: 14.

10. The bispecific antibody according to claim 3 , wherein the heavy chain variable region of the anti-CD3 antibody comprises a CDR1 consisting of amino acids 31 to 35 of SEQ ID NO: 14, a CDR2 consisting of amino acids 50 to 68 of SEQ ID NO: 14, and a CDR3 consisting of amino acids 101 to 114 of SEQ ID NO: 14, and the light chain variable region of the anti-CD3 antibody comprises a CDR1 consisting of amino acids 168 to 181 of SEQ ID NO: 14, a CDR2 consisting of amino acids 197 to 203 of SEQ ID NO: 14, and a CDR3 consisting of amino acids 236 to 244 of SEQ ID NO: 14.

11. The bispecific antibody according to claim 1 , wherein the heavy chain variable region of the anti-CD3 antibody consists of amino acids 1 to 125 of SEQ ID NO: 14, and the light chain variable region of the anti-CD3 antibody consists of amino acids 146 to 254 of SEQ ID NO: 14.

12. The bispecific antibody according to claim 4 , wherein the heavy chain variable region of the anti-CD3 antibody consists of amino acids 1 to 125 of SEQ ID NO: 14, and the light chain variable region of the anti-CD3 antibody consists of amino acids 146 to 254 of SEQ ID NO: 14.

13. The bispecific antibody according to claim 5 , wherein the heavy chain variable region of the anti-CD3 antibody consists of amino acids 1 to 125 of SEQ ID NO: 14, and the light chain variable region of the anti-CD3 antibody consists of amino acids 146 to 254 of SEQ ID NO: 14.

14. The bispecific antibody according to claim 1 , wherein the anti-CD3-scFv region consists of amino acids 1 to 254 of SEQ ID NO: 14.

15. The bispecific antibody according to claim 1 , wherein the Fc region comprises a LALA mutation, a N297G mutation, and a knobs-into-holes mutation, wherein the knobs-into-holes mutation is T366W mutation in one Fc polypeptide included in the Fc region, and T366S, L368A and Y407V mutation in another Fc polypeptide included in the Fc region, wherein positions of mutation are amino acid positions in human Igyl constant region according to EU index.

16. The bispecific antibody according to claim 1 , wherein the first Fc polypeptide consists of amino acids 235 to 451 of SEQ ID NO: 6 and the second Fc polypeptide consists of amino acids 270 to 486 of SEQ ID NO: 14.

17. The bispecific antibody according to claim 1 , wherein the heavy chain fragment of the anti-TSPAN8 antibody and the first Fc polypeptide are linked through a hinge region, and the anti-CD3-scFv region and the second Fc polypeptide are linked through a hinge region.

18. The bispecific antibody according to claim 1 fur

Assignees

• Astellas Pharma Inc
• Nat Cancer Ct

Inventors

• Tenda Yoshiyuki
• Yuri Masatoshi
• Yamajuku Daisuke
• Tsutsumi Takeshi
• Kusuzaki Yuko
• Sasaki Hiroki
• Chiwaki Fumiko
• Komatsu Masayuki

Classifications

• C07K16/28 Primary

  against receptors, cell surface antigens or cell surface determinants · CPC title

• A61P35/00 Primary

  Antineoplastic agents · CPC title

• C07K16/2809

  against the T-cell receptor (TcR)-CD3 complex · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K2317/21

  from primates, e.g. man · CPC title